RC-3095 (TFA)

RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2].

Product Specifications

CAS Number

[1217463-61-0]

UNSPSC

12352209

Target

Bombesin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rc-3095-tfa.html

Purity

98.92

Solubility

H2O : 40 mg/mL (ultrasonic)

Smiles

O=C([C@H]1CC(C(C=CC=C2)=C2N3)=C3CN1)N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N[C@@H](CC(C)C)CN[C@H](C(N)=O)CC(C)C)=O)CC4=CN=CN4)=O)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O.OC(C(F)(F)F)=O

Molecular Formula

C58H80F3N15O11

Molecular Weight

1220.34

References & Citations

[1]Oliveira PG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011 Oct;63 (10) :2956-65.|[2]Roesler R, et al. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol. 2004 Feb 13;486 (1) :35-41.